# PERCIST Criteria for Response Evaluation With Solid Tumors

> **NCT02765620** · — · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Lung Neoplasms
- Breast Neoplasms
- Colonic Neoplasms
- Lymphoma

## Interventions

- **OTHER:** drug&radiation

## Key facts

- **NCT ID:** NCT02765620
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04
- **Primary completion:** 2018-01
- **Final completion:** 2018-04
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2016-05-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02765620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02765620, "PERCIST Criteria for Response Evaluation With Solid Tumors". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02765620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*